Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

Prime Therapeutics researchers share more about award-winning real-world research

*Orphan drug status intravenous (IV); Prescription Drug User Fee Act (PDUFA) Cell therapy: Aims to replace or repair damaged cells through transplantation of healthy ones Editorial team Editor's...

Editor's message Editorial team Cell therapy= Transplantation of healthy cells to replace or repair damaged ones *Orphan drug status PDUFA= Prescription Drug User Fee Act IV= intravenous...

Specialty Pharmacy Continuum

Managed Healthcare Executive

Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy

Academy of Managed Care Pharmacy (AMCP)

BioPharma Dive: There are no drugs specifically for polycystic ovary syndrome, a chronic condition that can cause infertility. One study is testing whether Wegovy might be beneficial.

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the cost impact of GLP-1 medications, offering critical...

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

Star Tribune

Editor's message Gene therapy= Aims to fix a faulty gene or replace it with a healthy gene to try to cure a disease or help the body become better at fighting disease Maryam Tabatabai, PharmD...

In the latest episode of the “Pharmacy Friends” podcast, hear about a new clinical report from Prime Therapeutics that dives into the latest evidence-based insights related to the rising prevalence...

Shortages in the manufacturing chain have led to label hopping and an increase in off-label use

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care

According to an analysis led by US-based Prime Therapeutics and published in the Journal of Managed Care & Specialty Pharmacy in August, on average only one-third of people continue taking GLP-1...